Statement<\/strong><\/p>\nThis press release contains forward-looking statements. These statements constitute \u201cforward-looking\u201d statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as \u201cwill,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cfuture,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201ctarget,\u201d \u201cconfident\u201d and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock\u2019s beliefs and expectations, are forward-looking statements.\u00a0Such statements are based upon management\u2019s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock\u2019s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.<\/p>\n
Non-GAAP<\/strong> Measures<\/strong><\/p>\nIn evaluating the business, the Company considers and uses non-GAAP measures, such as non-GAAP gross profit and non-GAAP gross margin, as supplemental measures to review and assess operating performance and formulate business plans. However, the presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America (\u201cU.S. GAAP\u201d). These non-GAAP financial measures may be different from non-GAAP methods of accounting and reporting used by other companies, including peer companies, and therefore their comparability may be limited.<\/p>\n
The Company defines non-GAAP gross profit as gross profit excluding depreciation and amortization. The Company defines non-GAAP gross margin as non-GAAP gross profit divided by its revenue.<\/p>\n
The Company believes presenting non-GAAP gross profit and non-GAAP gross margin excluding non-cash impact of depreciation and amortization, in addition to the Company\u2019s GAAP gross profit and gross margin, provides a better understanding of the underlying trends in the Company\u2019s operating business performance.<\/p>\n
Reconciliation of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures are set forth at the end of this press release, all of which should be considered when evaluating the Company\u2019s performance.<\/p>\n
Contact: IR@brbiotech.com<\/a><\/p>\n
\n\nSelected Operating Data
<\/strong><\/td>\n<\/tr>\n\n| \u00a0<\/td>\n | \u00a0<\/td>\n<\/tr>\n | \n| \u00a0<\/td>\n | As of
<\/strong><\/td>\n<\/tr>\n\n| \u00a0<\/td>\n | June\u00a0<\/strong>30,<\/strong><\/td>\nSeptember\u00a030,<\/strong><\/td>\nDecember\u00a031,<\/strong><\/td>\nMarch\u00a0<\/strong>31,<\/strong><\/td>\nJune\u00a0<\/strong>30,<\/strong><\/td>\n<\/tr>\n\n| \u00a0<\/td>\n | 2025<\/strong><\/td>\n2025<\/strong><\/td>\n2025<\/strong><\/td>\n2026<\/strong><\/td>\n2026<\/strong><\/td>\n<\/tr>\n\nIn-hospital<\/strong> channel:<\/strong><\/td>\n| \u00a0<\/td>\n | \u00a0<\/td>\n | \u00a0<\/td>\n | \u00a0<\/td>\n | \u00a0<\/td>\n<\/tr>\n | \n| Pipeline partner hospitals(1)<\/td>\n | 30<\/td>\n | 31<\/td>\n | 30<\/td>\n | 30<\/td>\n | 30<\/td>\n<\/tr>\n | \n| Contracted partner hospitals(2)<\/td>\n | 63<\/td>\n | 63<\/td>\n | 64<\/td>\n | 64<\/td>\n | 64<\/td>\n<\/tr>\n | \nTotal number<\/strong> of partner<\/strong> hospitals<\/strong><\/td>\n93<\/strong><\/td>\n94<\/strong><\/td>\n94<\/strong><\/td>\n94<\/strong><\/td>\n| 94<\/strong><\/td>\n<\/tr>\n<\/table>\n <\/p>\n \n\n| (1)<\/td>\n | Refers to hospitals that are in the process of establishing in-hospital laboratories, laboratory equipment procurement or installation, staff training or pilot testing using the Company\u2019s products.<\/td>\n<\/tr>\n | \n| (2)<\/td>\n | Refers to hospitals that have entered into contracts to purchase the Company\u2019s products for use on a recurring basis in their respective in-hospital laboratories the Company helped them establish. Kit revenue is generated from contracted hospitals.<\/td>\n<\/tr>\n | \n| \u00a0<\/td>\n | \u00a0<\/td>\n<\/tr>\n<\/table>\n <\/p>\n \n\nSelected Financial Data
<\/strong><\/td>\n<\/tr>\n\n| \u00a0<\/td>\n | \u00a0<\/td>\n | \u00a0<\/td>\n | \u00a0<\/td>\n | \u00a0<\/td>\n | \u00a0<\/td>\n<\/tr>\n | \n| \u00a0<\/td>\n | For the three months ended
<\/strong><\/td>\n<\/tr>\n\n| \u00a0<\/td>\n | June\u00a0<\/strong>30,<\/strong><\/td>\nSeptember\u00a030,<\/strong><\/td>\nDecember\u00a031,<\/strong><\/td>\nMarch\u00a0<\/strong>31,<\/strong><\/td>\nJune\u00a0<\/strong>30,<\/strong><\/td>\n<\/tr>\n\nRevenues<\/strong><\/td>\n2025<\/strong><\/td>\n2025<\/strong><\/td>\n2025<\/strong><\/td>\n2026<\/strong><\/td>\n2026<\/strong><\/td>\n<\/tr>\n\n| \u00a0<\/td>\n | \u00a0<\/td>\n | (RMB<\/strong> in<\/strong> thousands)<\/strong><\/td>\n| \u00a0<\/td>\n<\/tr>\n | \n| Central laboratory channel<\/td>\n | 40,861<\/td>\n | 36,811<\/td>\n | 44,025<\/td>\n | 32,420<\/td>\n | 36,782<\/td>\n<\/tr>\n | \n| In-hospital channel<\/td>\n | 62,496<\/td>\n | 52,847<\/td>\n | 51,005<\/td>\n | 52,761<\/td>\n | 67,145<\/td>\n<\/tr>\n | \n| Pharma research and development channel<\/td>\n | 45,197<\/td>\n | 41,959<\/td>\n | 31,285<\/td>\n | 22,762<\/td>\n | 30,838<\/td>\n<\/tr>\n | \nTotal<\/strong> revenues<\/strong><\/td>\n148,554<\/strong><\/td>\n131,617<\/strong><\/td>\n126,315<\/strong><\/td>\n107,943<\/strong><\/td>\n| 134,765 <\/strong><\/td>\n<\/tr>\n<\/table>\n \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/p>\n \n\n| \u00a0<\/td>\n | For the three months ended
<\/strong><\/td>\n<\/tr>\n\n| \u00a0<\/td>\n | June\u00a0<\/strong>30,<\/strong><\/td>\nSeptember\u00a030,<\/strong><\/td>\nDecember\u00a031,<\/strong><\/td>\nMarch\u00a0<\/strong>31,<\/strong><\/td>\nJune\u00a0<\/strong>30,<\/strong><\/td>\n<\/tr>\n\nRevenues<\/strong> by<\/strong> location<\/strong> of<\/strong> contracting<\/strong> customer<\/strong><\/td>\n2025<\/strong><\/td>\n2025<\/strong><\/td>\n2025<\/strong><\/td>\n2026<\/strong><\/td>\n2026<\/strong><\/td>\n<\/tr>\n\n| \u00a0<\/td>\n | \u00a0<\/td>\n | (RMB<\/strong> in<\/strong> thousands)<\/strong><\/td>\n| \u00a0<\/td>\n<\/tr>\n | \n| Overseas<\/td>\n | 37,458<\/td>\n | 17,214<\/td>\n | 21,849<\/td>\n | 8,544<\/td>\n | 17,878<\/td>\n<\/tr>\n | \n| Chinese mainland<\/td>\n | 111,096<\/td>\n | 114,403<\/td>\n | 104,466<\/td>\n | 99,399<\/td>\n | 116,887<\/td>\n<\/tr>\n | \nTotal<\/strong> revenues<\/strong><\/td>\n148,554<\/strong><\/td>\n131,617<\/strong><\/td>\n126,315<\/strong><\/td>\n107,943<\/strong><\/td>\n| 134,765<\/strong><\/td>\n<\/tr>\n<\/table>\n \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/p>\n \n\n| \u00a0<\/td>\n | For the three months ended
<\/strong><\/td>\n<\/tr>\n\n| \u00a0<\/td>\n | June\u00a0<\/strong>30,<\/strong><\/td>\nSeptember\u00a030,<\/strong><\/td>\nDecember\u00a031,<\/strong><\/td>\nMarch\u00a0<\/strong>31,<\/strong><\/td>\nJune\u00a0<\/strong>30,<\/strong><\/td>\n<\/tr>\n\nGross<\/strong> profit<\/strong><\/td>\n2025<\/strong><\/td>\n2025<\/strong><\/td>\n2025<\/strong><\/td>\n2026<\/strong><\/td>\n2026<\/strong><\/td>\n<\/tr>\n\n| \u00a0<\/td>\n | \u00a0<\/td>\n | (RMB<\/strong> in<\/strong> thousands)<\/strong><\/td>\n| \u00a0<\/td>\n<\/tr>\n | \n| Central laboratory channel<\/td>\n | 35,937<\/td>\n | 30,126<\/td>\n | 39,322<\/td>\n | 28,761<\/td>\n | 31,510<\/td>\n<\/tr>\n | \n| In-hospital channel<\/td>\n | 46,490<\/td>\n | 37,925<\/td>\n | 38,388<\/td>\n | 38,458<\/td>\n | 51,760<\/td>\n<\/tr>\n | \n| Pharma research and development channel<\/td>\n | 25,676<\/td>\n | 30,793<\/td>\n | 20,856<\/td>\n | 10,789<\/td>\n | 14,543<\/td>\n<\/tr>\n | \nTotal<\/strong> gross<\/strong> profit<\/strong><\/td>\n108,103<\/strong><\/td>\n98,844<\/strong><\/td>\n98,566<\/strong><\/td>\n78,008<\/strong><\/td>\n| 97,813 <\/strong><\/td>\n<\/tr>\n<\/table>\n \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/p>\n \n\n| \u00a0<\/td>\n | For<\/strong> the<\/strong> three<\/strong> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |